PMID: 6110210Jan 1, 1981Paper

Differential actions of classical and atypical antipsychotic drugs on spontaneous neuronal activity in the amygdaloid complex

Pharmacology, Biochemistry, and Behavior
G V RebecT R Bashore

Abstract

Classical antipsychotic drugs such as haloperidol produce akinesia and catalepsy, whereas clozapine and related atypical antipsychotics fail to elicit these behaviors even at relatively high doses. Despite these behavioral differences, a cataleptic dose of haloperidol (2.0 mg/kg) produces changes in neuronal activity in the neostriatum and nucleus accumbens comparable to those produced by a non-cataleptic dose of clozapine (20.0 mg/kg). To further elucidate the brain mechanisms underlying the differential behavioral response to these drugs, an electrophysiological analysis was extended to neurons in the rat amygdaloid complex. Whereas an intraperitoneal injection of 2.0 mg/kg haloperidol generally failed to alter the firing rate of amygdaloid neurons, 20.0 mg/kg clozapine typically produced a prolonged increase in activity. Similarly, clozapine, but not haloperidol, reversed the depression of firing rate produced by 1.0 mg/kg d-amphetamine. The results suggest that neurons in the amygdaloid complex are more responsive to antipsychotic drugs devoid of extrapyramidal side effects than to antipsychotics which elicit parkinsonian-like motor dysfunctions.

References

Aug 15, 1977·European Journal of Pharmacology·M Stanley, S Wilk
Jan 1, 1979·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·H R Bürki
Aug 1, 1975·European Journal of Pharmacology·B H Westerink, J Korf
May 15, 1975·Biochemical Pharmacology·O Hornykiewicz
Sep 1, 1975·European Journal of Pharmacology·B Costall, R J Naylor
Jan 31, 1978·Psychopharmacology·G M SimpsonR K Shrivastava
Mar 9, 1978·Nature·J E LeysenP M Laduron
Jan 1, 1978·Annual Review of Neuroscience·R Y Moore, F E Bloom
Jan 1, 1976·Annual Review of Psychology·P M Groves, G V Rebec
May 1, 1975·Pharmakopsychiatrie, Neuro-Psychopharmakologie·H R BürkiT G White
Jan 1, 1976·Psychopharmacologia·W RuchH R Bürki
Feb 1, 1974·European Journal of Pharmacology·B Costall, R J Naylor
Oct 25, 1974·Brain Research·M BrownsteinM Palkovits
Feb 1, 1969·Journal of Comparative and Physiological Psychology·L Stein, C D Wise
Oct 1, 1965·The Journal of Pharmacy and Pharmacology·D W Straughan, K F Legge
Aug 1, 1973·European Journal of Pharmacology·H H KellerA Pletscher
Aug 1, 1973·Neuropharmacology·G BartholiniA Pletscher
Mar 1, 1980·Neuropharmacology·G V RebecK D Alloway

❮ Previous
Next ❯

Citations

Jan 1, 1988·Physiology & Behavior·A RayR M Sullivan
Aug 1, 1983·Pharmacology, Biochemistry, and Behavior·G V Rebec, E H Lee
Jun 1, 1986·Pharmacology, Biochemistry, and Behavior·G D Anderson, G V Rebec
Nov 1, 1990·Neuroscience and Behavioral Physiology·V A Feshchenko, L I Chilingaryan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.